Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
16 10월 2023 - 7:05AM
Business Wire
Highlights include a new analysis showing that Tumor Treating
Fields therapy, when added to standard systemic therapies, did not
adversely affect patients’ quality of life in the phase 3 LUNAR
clinical trial.
Novocure (NASDAQ: NVCR) today announced its participation in the
European Society for Medical Oncology (ESMO) Congress 2023 from
October 20 – 24 in Madrid. Novocure will present three new posters
on Tumor Treating Fields (TTFields) therapy, including an analysis
of patient-reported health-related global and functional quality of
life scores from the randomized phase 3 LUNAR clinical trial in
metastatic non-small cell lung cancer (NSCLC).
The new analysis of data from LUNAR utilized The European
Organization for Research and Treatment of Cancer Quality of Life
questionnaire-C30. Analysis showed no statistically significant
difference between patients who received TTFields therapy together
with standard systemic therapies and patients who received standard
systemic therapies alone in median time to deterioration for global
health status (4.4 vs 4.0 months, P=0.91) and for all five
functional scales: physical functioning (3.2 vs 4.2 months,
P=0.58), role functioning (3.0 vs 2.8 months, P=0.59), emotional
functioning (6.6 vs 5.7 months, P=0.96), cognitive functioning (3.7
vs 4.4 months, P=0.23), and social functioning (4.0 vs 3.9 months,
P=0.66).
Highlights of Novocure’s presentations at the ESMO Congress 2023
also include global post-marketing surveillance data from patients
with high-grade gliomas, confirming the well-tolerated safety
profile of TTFields therapy in a subgroup of patients ages 70 and
older in the real-world setting, which is consistent with data from
Novocure’s EF-14 clinical trial. Another highlight is survey data
from patients with glioblastoma (GBM) using TTFields therapy in the
United States and DACH region (Germany, Austria and Switzerland),
which showed that most patients were very satisfied or satisfied
with TTFields therapy. Most said they would recommend TTFields
therapy to a friend or acquaintance with GBM.
Novocure will also host an industry-sponsored symposium, titled
The Evolving Role of TTFields Therapy in Solid Tumors, in Oviedo
Auditorium, Hall 7, on Oct. 23 at 1 p.m. CEST.
“We are encouraged by new data supporting the use of TTFields
therapy in the management of metastatic NSCLC and further
validating the favorable safety and patient satisfaction profiles
of TTFields therapy in patients with aggressive central nervous
system tumors,” said Pritesh Shah, Novocure’s Chief Growth Officer.
“We look forward to sharing these insights with, and continuing to
learn from, leading medical oncologists in Europe and
worldwide.”
Novocure’s full list of presentations at the ESMO Congress 2023
includes:
- Post-marketing surveillance data from patients ≥70 years of
age with central nervous system malignancies treated with Tumor
Treating Fields (TTFields) therapy between 2011–2022.
Presenter: Wenyin Shi. 12 p.m. CEST on Sunday, Oct. 22.
- Tumor Treating Fields therapy for glioblastoma: Identifying
needs and satisfaction of new and long-term users. Presenter:
Eleni Batzianouli. 12 p.m. CEST on Sunday, Oct. 22.
- Impact of TTFields therapy on global and functional
health-related quality of life (HRQoL) in metastatic non-small cell
lung cancer (mNSCLC) from the pivotal LUNAR study. Presenter:
Joachim Aerts. 12 p.m. CEST on Monday, Oct. 23.
- Symptom burden and health-related quality of life (HRQoL) in
platinum-resistant or -refractory ovarian cancer (PROC): a
systematic literature review (SLR). Presenter: Nikhila
Indukuri. 12 p.m. CEST on Saturday, Oct. 21.
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) are electric fields that exert
physical forces to kill cancer cells via a variety of mechanisms.
TTFields do not significantly affect healthy cells because they
have different properties (including division rate, morphology, and
electrical properties) than cancer cells. The multiple, distinct
mechanisms of TTFields therapy work together to selectively target
and kill cancer cells. Due to its multimechanistic actions,
TTFields therapy can be added to cancer treatment modalities in
approved indications and demonstrates enhanced effects across solid
tumor types when used with chemotherapy, radiotherapy, immune
checkpoint inhibition, or targeted therapies in preclinical models.
TTFields therapy provides clinical versatility that has the
potential to help address treatment challenges across a range of
solid tumors. To learn more about Tumor Treating Fields therapy and
its multifaceted effect on cancer cells, visit
tumortreatingfields.com.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical trial progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions as well as issues arising from the COVID-19
pandemic and other more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2023, and subsequent filings with the U.S.
Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements. Furthermore, Novocure does
not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak
only as of the date hereof. The Private Securities Litigation
Reform Act of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231015665808/en/
Investors: Ingrid Goldberg investorinfo@novocure.com
610-723-7427
Media: Leigh Labrie media@novocure.com 610-723-7428
NovoCure (NASDAQ:NVCR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
NovoCure (NASDAQ:NVCR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024